Among 107 @entity1358 ( @entity1358 ) @entity1 with histopathologic subtype diagnosis who were treated at Albert Einstein @entity5 Center with cytokines over a 10-year period, seven @entity1 had @entity1358 histology, 63 had @entity1358 , and 10 @entity1 had mixed histology ( @entity1358 and clear cell). Regardless of their histology, @entity1 with a disease free interval of 2 years or more had significantly better survival. None of the @entity1 with @entity1358 histology responded to therapy. However, several @entity1 with mixed and clear cell histology achieved partial or complete responses following high dose @entity1199 ( @entity1199 ) therapy. The median survival of @entity1 with @entity1358 histology was the shortest (13.8 months), whilst that of @entity1 with mixed and clear cell histology was much longer (34.8 months and 39.1 months, respectively). This result was statistically significant in both univariate and multivariate survival analysis (P < 0.001 and P < 0.01, respectively). @entity1 with mixed and clear cell histology had no significant difference in survival, and their median survival combined was significantly longer than that of @entity1 with @entity1358 histology (P < 0.0001 in univariate analysis, P < 0.01 in multivariate analysis). This study suggests that survival with a diagnosis of @entity1358 is predicted by @entity5 histology and disease free interval, and this impacts on the ability to respond to standard therapy. @entity1 with mixed and clear cell histology respond to cytokine therapy. Other therapies should be sought for @entity1 with @entity1358 @entity1358 .

Impact of histology on the treatment outcome of metastatic or recurrent XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity1199 :: ('3558', 'Gene') :: ['IL-2', 'Interleukin-2'] @entity1358 :: ('MESH:D002292', 'Disease') :: ['renal cell carcinoma', 'clear cell carcinoma', 'sarcomatoid', 'RCC'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Cancer']
@entity1358 :: (MESH:D002292,Disease) :: ['renal cell carcinoma']
